SEC Form 4 · accession 0001179110-17-014106
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Nov 10, 2017
Accepted (ET)
Nov 14, 2017 · 3:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 10, 2017 | G | 5,600 | $0.00 | D | 283,005 | D | |
| Common StockF2 | Nov 13, 2017 | P | 5,600 | $4.84 | A | 288,605 | D | |
| Common Stock | holding | — | — | — | 193,318 | I | By spouse trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a gift of 5,600 shares to a non-profit organization, and, subsequently, there was a purchase of 5,600 shares in the open market, as reported on the next line of this Form 4.
- F2Represents the purchase of 5,600 shares in multiple transactions, ranging in price from $4.825 to $4.850 per share, resulting in a weighted average purchase price per share of $4.840. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range.